REG - Feedback PLC - Award of Pilot Funding

FeedbackAnnouncement

19/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231219:nRSS2189Xa&default-theme=true

RNS Number : 2189X  Feedback PLC  19 December 2023

Prior to publication, the information contained within this announcement was
deemed by the Company to constitute inside information as stipulated under the
Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of
this announcement, this information is now considered to be in the public
domain.

 

Feedback plc

 

Feedback awarded pilot funding to undertake further CDC pathway development

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical
infrastructure specialist, announces it is conducting a series of pilot
programmes of Community Diagnostic Centre ("CDC") care pathways funded by a
combined award of £300,000. The Company has directly contracted with the
individual NHS organisations hosting the pilot sites utilising funds locally
disbursed for this purpose under NHS England's ("NHSE"), Community Diagnostic
Centre Programme.

 

These pilots, which will initially run until 31 March 2024, will build on
Feedback's pilot contract for the Sussex ICS with QVH and aim to further
demonstrate the impact of a pathway approach on CDC utilisation and wider
patient wait times. The pilot implementations will also facilitate GP Direct
access into CDC diagnostic services.

 

Two pilot sites are participating in the programme - Amersham CDC in
Buckinghamshire and a pan regional pilot across Buckinghamshire, Oxfordshire
and Berkshire ICS (BOB ICS), looking at multiple service lines and mutual aid
delivery models for sharing workforce capacity at a regional basis through the
Bleepa platform.

 

The evidence generated by these pilots will build the case for subsequent
funding of a pathway approach to CDC delivery in subsequent financial years
and NHSE will be closely monitoring the pilot outcome data as the programme
rolls out in order to inform forward planning.

 

Dr Tom Oakley, CEO of Feedback plc said: "We are delighted to have the
opportunity to further build the evidence base for a pathway approach to CDCs
using Bleepa. This will generate the results back into the clinical pathway,
under the noses of decision makers and enable them to facilitate a robust
clinical dialogue to transform results into care decisions.

 

"Bleepa has already demonstrated a 69% reduction in wait times through the
power of asynchronous communication and a pathway approach with Queen Victoria
Hospital in Sussex. This is the sort of impact data that will support the NHS
to address elective care backlogs and to help ease winter pressures. It is a
privilege to work with a number of new NHS partners to help them deliver this
impact for their patients and staff.

 

"The team very much look forward to commencing these pilots and further
strengthening our relationship with the NHS, which provides funding for a
number of vanguard projects to champion the adoption and use of digital
technology and innovation in care pathways."

 

--Ends--

Enquiries:

 

 Feedback plc                                    +44 (0) 20 3997 7634

 Tom Oakley, CEO                                 IR@fbk.com (mailto:IR@fbk.com)

 Anesh Patel, CFO

 Panmure Gordon (UK) Limited (NOMAD and Broker)  +44 (0)20 7886 2500

 Emma Earl/Freddy Crossley (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd;                                Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                                 (mailto:feedbackplc@walbrookpr.com)
 Nick Rome/Joe Walker                            07748 325 236 or 07407 020 470

 

 

About Feedback

 

Feedback plc helps clinical teams to make better decisions faster for
patients. We design products that enhance clinician access to patient data and
to their colleagues. Our unique approach centres around individual patient
episodes, into which we pull relevant clinical data from hospital systems and
around which we build remote clinical teams for collaboration. As a result, we
produce a digital infrastructure that makes patient data available to
clinicians in multiple settings, in a format that enables them to meaningfully
interact with it, providing flexibility to clinicians and free movement of
patients between provider settings - clinicians can practice from anywhere and
patients can attend any care provider for treatment.

 

Our products Bleepa and CareLocker work together to deliver unparalleled value
to our customers. Bleepa is our application layer and sits on top of
CareLocker as our data layer. Bleepa is a clinician facing platform that
displays clinical results from a patient's CareLocker at a certified and
regulated quality, that is suitable for clinical use and enables dialogue on a
patient-by-patient basis with colleagues through a secure, auditable chat
interface that links back to the patient medical record. The CareLocker data
storage model is built around the patient. Our vision is one where relevant
clinical data is always available to the patient as well as to any care
setting that they may attend - a federated data architecture with the patient
as the tenant.

 

The Company has a number of growth opportunities domestically and
internationally across a range of markets including the NHS, the veterinary
market and private healthcare providers and its highly scalable Software as a
Service ("SaaS")-based model is expected to provide increasing levels of
revenue visibility as the Company grows its customer base.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFVLLFXLLFFBV